Search Results - "Garcia, P Borrega"

ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy by Magallón-Pedrera, I., Pérez-Altozano, J., Virizuela Echaburu, J. A., Beato-Zambrano, C., Borrega-García, P., de la Torre-Montero, J. C.

“…Purpose Cancer patients require implantation of venous access devices to meet their personalized therapeutic needs, which are often complex due to the nature…”
Get full text

Clinical guide SEOM on venous thromboembolism in cancer patients by Muñoz Martín, A. J., Font Puig, C., Navarro Martín, L. M., Borrega García, P., Martín Jiménez, M.

“…Venous thromboembolism (VTE) is a common event in cancer patients and one of the major causes of cancer-associated mortality and a leading cause of morbidity…”
Get full text

Clinical guideline SEOM: cancer of unknown primary site by Collado Martín, R., García Palomo, A., de la Cruz Merino, L., Borrega García, P., Barón Duarte, F. J.

“…Cancer of unknown primary site is a histologically confirmed cancer which is manifested in advanced stage, with no identifiable primary site after the use of…”
Get full text

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study by Pérez-Valderrama, B., Arranz Arija, J.A., Rodríguez Sánchez, A., Pinto Marín, A., Borrega García, P., Castellano Gaunas, D.E., Rubio Romero, G., Maximiano Alonso, C., Villa Guzmán, J.C., Puertas Álvarez, J.L., Chirivella González, I., Méndez Vidal, M.J., Juan Fita, M.J., León-Mateos, L., Lázaro Quintela, M., García Domínguez, R., Jurado García, J.M., Vélez de Mendizábal, E., Lambea Sorrosal, J.J., García Carbonero, I., González del Alba, A., Suárez Rodríguez, C., Jiménez Gallego, P., Meana García, J.A., García Marrero, R.D., Gajate Borau, P., Santander Lobera, C., Molins Palau, C., López Brea, M., Fernández Parra, E.M., Reig Torras, O., Basterretxea Badiola, L., Vázquez Estévez, S., González Larriba, J.L.

“…Patients with metastatic renal carcinoma (mRCC) treated with first-line pazopanib were not included in the International Metastatic Renal Cell Carcinoma…”
Get full text

Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E., Mejorada, R Lozano, Saez, M., De Giorgi, U.F.F., Aragón, I., Laorden, N Romero, De Velasco Oria de Rueda, G.A., Magraner, L., Pacheco, M.I., Puente, J., del Alba, A González, Garcia, P Borrega, Conteduca, V., Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A., Colmenero, A Medina, Barrera, R Morales, Lorente, D., Hidalgo, D Olmos

Get full text

876P - Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E., Mejorada, R Lozano, Saez, M., De Giorgi, U.F.F., Aragón, I., Laorden, N Romero, De Velasco Oria de Rueda, G.A., Magraner, L., Pacheco, M.I., Puente, J., del Alba, A González, Garcia, P Borrega, Conteduca, V., Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A., Colmenero, A Medina, Barrera, R Morales, Lorente, D., Hidalgo, D Olmos

“…Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately repair DSBs and a…”
Get full text

876PImpact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E, Mejorada, R Lozano, Saez, M, De Giorgi, U F F, Aragón, I, Laorden, N Romero, De Velasco Oria de Rueda, G A, Magraner, L, Pacheco, M I, Puente, J, del Alba, A González, Garcia, P Borrega, Conteduca, V, Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A, Colmenero, A Medina, Barrera, R Morales, Lorente, D, Hidalgo, D Olmos

“…Abstract Background Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately…”
Get full text

Correlation between toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients by de Miguel, P. Ayala, Díez, S. Arnáiz, García, I. Gorospe, Gallego, J. López, Varella, A. Illán, García, P. Borrega

Get full text

Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors by de Miguel, P. Ayala, Gallego, J. López, García, I. Gorospe, Varella, A. Illán, Vargas, P.R. Rivera, Restrepo, A. Posada, García, P. Borrega

Get full text

1331P Correlation between development and grade of immune-related toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients by Ayala de Miguel, P., Gallego, J. López, García, I. Gorospe, Vargas, P.R. Rivera, Restrepo, A. Posada, Caballero, A. Acero, Machado, J. Aires, Calderón, R. Alonso, García, J.M. Rodríguez, García, P. Borrega

Get full text

639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide by Carles, J., Alonso, T., Mellado Gonzalez, B., Mendez Vidal, M.J., Vazquez Estevez, S., González del Alba, A., Piulats, J.M., Borrega García, P., Gallardo, E., Morales Barrera, R., Paredes, P., Reig, O., Garcías de España, C., Collado, R., Bonfill, T., Suarez, C., Malfettone, A., Garde, J.

Get full text

628P Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone by Llacer Perez, C., Romero Laorden, N., Lozano Mejorada, R., Piulats, J.M., Puente, J., Lorente Estelles, D., Medina, A., Cattrini, C., Vitrone, F.M., Almagro, E., Borrega García, P., Lainez, N., Rivera, L., Villatoro, R., Hernández, A., Rodriguez-Vida, A., López-Casas, P.P., Gallardo, E., Castro Marcos, E., Olmos Hidalgo, D.

Get full text

SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials by Arranz Arija, J., Pérez Valderrama, B., Rodríguez Sánchez, Á., Chirivella González, I., Anido Herranz, U., Maroto Rey, J.P., Miranda Pallares, M.J., Climent Duran, M.A., Crespo Herrero, G., Meana Garcia, J.A., Rodriguez-Vida, A., Fernandez-Rodriguez, R., Santander, C., Rubio Romero, G., Vazquez Estevez, S., Fernandez Calvo, O., Gonzalez Gragera, M.B., Almagro Casado, E., Perez Ramirez, S., Borrega García, P.

Get full text

PRORADIUM: Prospective multicentre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with radium-223 by Morales Barrera, R., Sáez, M.I., Romero-Laorden, N., Lozano Mejorada, R., Lorente Estelles, D., de Velasco, G., Gonzalez Del Alba Baamonde, M.A., Gonzalez Billalabeitia, E., Medina, A., Borrega García, P., Rodriguez-Vida, A., Ferrandiz Brotons, U., Fernandez Calvo, O., García Domínguez, R., Puente, J., Piulats Rodriguez, J.M., Villatoro, R., Castro Marcos, E., Olmos Hidalgo, D.

Get full text

PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA) by Lorente Estelles, D., Puente, J., Medina, A., Lozano Mejorada, R., Rivera, L., Pacheco, M.I., Sáez, M.I., Piulats Rodriguez, J.M., Fernandez Parra, E.M., Borrega García, P., Pérez Valderrama, B., Gallardo Diaz, E., Villatoro, R., Morales Barrera, R., Vazquez Estevez, S., Pinto Marin, A., Contreras Ibañez, J.A., Romero Laorden, N., Castro Marcos, E.

Get full text

Abstract P6-07-21: High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study) by Manso Sánchez, L, Moreno Antón, F, Izarzugaza Perón, Y, Delgado Mingorance, I, Borrega García, P, Echarri González, MJ, Martínez Jáñez, N, López González, A, Olier Garate, C, Ballesteros García, A, Chacón López-Muñiz, I, Ciruelos Gil, EM, García Sáenz, JA, Paz-Ares Rodríguez, L

“…Abstract Background Circulating tumour cells (CTC) may be a good biomarker to guide the management of patients with LAMBC (Cristofanilli, NEJM 2004). Detection…”
Get full text

Primary endobronchial non-hodgkins lymphoma: description of a case and review of the literature by Reina Zoilo, J J, Ruiz Borrego, M, Valenzuela Claros, J C, Valladares Ayerbes, M J, Borrega García, P, Viana Alonso, A, Moreno Nogueira, J A

“…We report a case of primary endobronchial non-Hodgkin Lymphoma, an unusual extranodal lymphoma, in a 62 year old patient, which begins with malaise, marked…”
Get more information

A retrorectal paravertebral abscess and meningitis due to Clostridium clostridioforme by Borrega-García, P, Jiménez-Mejías, M E, Chinchón, I, Cuello-Contreras, J A

Get more information